Biodegradable Stents in Primary Sclerosing Cholangitis
Key facts
- Who runs it
- King's College Hospital NHS Trust
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 1 Apr 2027
- Type of study
- Interventional
- Treatments tested
- archimedes stent
- Record updated
- 29 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- PSC patients with a high grade stricture
Who cannot take part
- Prior stenting or balloon dilatation within the previous 4 months
- Change of UDCA therapy within 4 weeks
- Suspicion of cholangiocarcinoma, reflected by an imaging study suggestive of metastasis, MRCP with mass lesion with contrast enhancenment, or rise in CA19.9 of > 63 U/ml in the previous 4 months together with an absolute value > 130 U/ml
- HIV or acute or chronic hepatitis B or hepatitis C or substance (drug or alcohol) misure within the previous 2 years
- Signs of current malignancy other than basal cell carcinoma
- Estimated transplant free survival < 2 years as calculated by Mayo score > 2
- Signs of bacterial cholangitis as defined by definite cholangitis
- Inability to give informed consent
- Biliary cirrhosis with Child Pugh score > 8
- Life expectancy < 24 months
- Women pregnant at the time of screening
This trial is currently available in United Kingdom.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In patients with PSC, endoscopic therapy of strictures aims to improve cholestasis by relieving the biliary obstruction via endoscopic biliary dilatation with consideration of plastic stents in strictures refractory to dilatation due to the risk of pancreatitis and cholangitis . Short term stents have been shown to have similar recurrence-free rates compared to dilatation in a randomised control trial; however, this was terminated after interim analysis due to higher rates of serious adverse events in the stent group. The long term benefits are unclear; however, it may lead to improved survival compared to predicted survival. In this group of patients with limited treatment options, biodegradable stents may provide an attractive additional treatment modality in the management of high grade strictures.
The group in the trial
- Archimedes stent insertionTreatment being tested
Archimedes stent insertion at ERCP for patients with PSC and a HGS
Treatment: archimedes stent
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of Biodegradable STents in Primary Sclerosing Cholangitis - BSTPSC
- Record updated
- 29 May 2026